PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
On the basis of remarkable antitumor activity, programmed death receptor-1 (PD-1) inhibitors pembrolizumab and nivolumab were approved for the treatment of advanced melanoma in the second-line setting following progression on either CTLA-4 inhibitor ipilimumab or BRAF/MEK inhibitors (for BRAF mutate...
Saved in:
Main Authors: | Diwakar Davar, Melissa Wilson, Chelsea Pruckner, John M. Kirkwood |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Case Reports in Oncological Medicine |
Online Access: | http://dx.doi.org/10.1155/2015/737389 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma
by: Chun Wai Wong, et al.
Published: (2025-01-01) -
Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
by: Rangarirai Makuku, et al.
Published: (2021-01-01) -
Immune Checkpoint Blockade in Melanoma – Earlier is Better?
by: Vincas Urbonas, et al.
Published: (2024-09-01) -
A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
by: Jin Bian, et al.
Published: (2022-01-01) -
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
by: Sandip P. Patel, et al.
Published: (2025-01-01)